Cited in:


This article has been cited by:

  1. 1
    Piotr Grabarczyk, Marco Koppelman, Fiona Boland, Silvia Sauleda, Cécile Fabra, Giuseppe Cambie, Aneta Kopacz, Karen O'Riordan, Harry van Drimmelen, Joan O'Riordan, Nico Lelie, Inclusion of human immunodeficiency virus Type 2 (HIV-2) in a multiplex transcription-mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: a multicenter performance evaluation study, Transfusion, 2015, 55, 9
  2. You have free access to this content2
    Roberta Bruhn, Nico Lelie, Michael Busch, Steven Kleinman, Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions, Transfusion, 2015, 55, 6
  3. 3
    Syria Laperche, C. Micha Nübling, Susan L. Stramer, Ewa Brojer, Piotr Grabarczyk, Hiroshi Yoshizawa, Vytenis Kalibatas, Magdy El Elkyabi, Faten Moftah, Annie Girault, Harry van Drimmelen, Michael P. Busch, Nico Lelie, Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples, Transfusion, 2015, 55, 10
  4. 4
    Manuel Álvarez, Mar Luis-Hidalgo, María Alma Bracho, Amando Blanquer, Luis Larrea, José Villalba, Nieves Puig, Dolores Planelles, José Montoro, Fernando González-Candelas, Roberto Roig, Transmission of human immunodeficiency virus Type-1 by fresh-frozen plasma treated with methylene blue and light, Transfusion, 2015, 55, 11
  5. You have free access to this content5
    Magdy El Ekiaby, Faten Moftah, Heidi Goubran, Harry van Drimmelen, Syria LaPerche, Steve Kleinman, Michael Busch, Nico Lelie, Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios, Transfusion, 2015, 55, 6
  6. 6
    Marion Vermeulen, Harry Drimmelen, Charl Coleman, Josephine Mitchel, Ravi Reddy, Nico Lelie, A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections, Transfusion, 2014, 54, 10
  7. 7
    K. T. Lin, C. L. Chang, M. H. Tsai, K. S. Lin, J. Saldanha, C. M. Hung, Detection and identification of occult HBV in blood donors in Taiwan using a commercial, multiplex, multi-dye nucleic acid amplification technology screening test, Vox Sanguinis, 2014, 106, 2
  8. 8
    Guilherme Albertoni, Manoel João Batista Castelo Girão, Nestor Schor, Mini review: Current molecular methods for the detection and quantification of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1, International Journal of Infectious Diseases, 2014, 25, 145


  9. 9
    V. Shyamala, Nucleic Acid Technology (NAT) testing for blood screening: impact of individual donation and Mini Pool – NAT testing on analytical sensitivity, screening sensitivity and clinical sensitivity, ISBT Science Series, 2014, 9, 2
  10. 10
    Piotr Grabarczyk, Bezpieczeństwo krwi w aspekcie badań wirusologicznych, Acta Haematologica Polonica, 2013, 44, 3, 294


  11. 11
    Marion Vermeulen, Charl Coleman, Josephine Mitchel, Ravi Reddy, Harry Drimmelen, Tracy Ficket, Nico Lelie, Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections, Transfusion, 2013, 53, 10pt2